Fujifilm has announced an update to its Instax Mini LiPlay that first launched in 2019. The new Instax Mini LiPlay Plus offers similar functionality as the original with the ability to snap digital photos that can be immediately printed on the…
Blog
-
Netanyahu ‘determined’ to pressure Hamas to find remaining dead hostages
EPABenjamin Netanyahu addressed a memorial ceremony at the Mount Herzl cemetery in Jerusalem Israel’s prime minister has told a memorial for victims of the Hamas-led attack on 7 October 2023 that he is “determined” to secure the return of the dead…
Continue Reading
-
Meta to shut down Messenger desktop apps for Mac and Windows
Meta is shutting down Messenger’s standalone desktop apps for Windows and Mac on December 15, the company confirmed to TechCrunch on Thursday.
Starting December 15, users will no longer be able to log into the apps and will be automatically…
Continue Reading
-
Pika, a new TikTok-like AI app, makes playful, creative short videos from just a few words
Welcome to Eye on AI, with AI reporter Sharon Goldman. In this edition…a TikTok-like AI video app that is built for Gen Z…Challenges renting San Francisco apartments during the AI boom…TSMC profit surges 39% to hit yet another record on AI…
Continue Reading
-
Earth’s magnetic field is shifting — and satellites are feeling it
More than a decade of satellite monitoring has mapped Earth’s magnetic field as it subtly altered between 2014 and 2025 — and what scientists have learned is remarkable. The South Atlantic Anomaly, a weak region, is expanding, the north…
Continue Reading
-
Immunotherapy EO2463 Receives FDA Fast Track for Follicular Lymphoma | Targeted Oncology
The FDA has granted fast track designation to the novel immunotherapy EO2463 for the treatment of follicular lymphoma, backed by positive interim data from the ongoing phase 2 SIDNEY trial (NCT04669171).1
Under this fast track designation, Enterome, the sponsor, will be eligible for more frequent opportunities for interaction with the FDA, rolling review, and potential eligibility for priority review if criteria are met, in hopes of bringing the therapy to patients sooner.2
“The FDA’s decision is an important validation of the unique potential of Enterome’s OncoMimics™ program,” said Pierre Belichard, chief executive officer of Enterome, in a news release.1 “It will expedite the clinical development and the regulatory pathways for EO2463, which is ready to enter registrational testing as early as next year after this fast track designation and a recent positive type C meeting with the FDA.”
What Is the Unmet Need in Follicular Lymphoma?
Follicular lymphoma, an indolent subtype of non-Hodgkin lymphoma (NHL), is characterized by slow disease progression and few symptoms yet shortened life expectancy, in part due to lack of a cure.
The condition exhibits potential for spontaneous remissions, suggesting the role of the immune system in such cases.3 While this invites an opportunity for treatment through immunotherapies, the disease’s high frequency of relapse necessitates immunotherapies that produce deep, durable antitumor responses.
How Is EO2463 Addressing This Need?
EO2463 is a novel therapeutic vaccine candidate that utilizes Enterome’s proprietary OncoMimics™ platform. Drugs that use this platform are designed using AI and machine learning to mimic tumor-associated antigens or lineage markers, drawing from a database of 23 million commensal bacteria genes to drive strong and lasting immune responses.1 Specifically, EO2463 is a combination of 4 synthetic OncoMimics™ microbial-derived peptides that correspond to 4 B cell markers: CD20, CD22, CD37, and CD268, as well as the CD4 helper-epitope UCP2.3
The nonrandomized, open-label phase 1/2 SIDNEY trial is evaluating the safety and preliminary efficacy of EO2463 monotherapy and in combination with lenalidomide (Revlimid) and/or rituximab (Rituxan) in patients with indolent NHL, including those with follicular lymphoma and marginal zone B-cell lymphoma, with an estimated enrollment of 60 patients across 4 cohorts.4
The primary outcome of phase 2 is objective response rate (ORR). In an early data report, the majority of patients remained on study treatment, with an observed ORR of 46% in the first 13 patients.5 Moreover, data presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting show that EO2463 monotherapy was well tolerated by patients, with no severe adverse events.3
This clinical activity primes EO2463 as a promising alternative treatment option for this patient population who may otherwise go untreated in a standard “watch-and-wait” approach.
REFERENCES:
1. Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463. News release. BioSpace. October 16, 2025. Accessed October 16, 2025.
https://tinyurl.com/4ahshump 2. Fast Track. US Food & Drug Administration. Updated August 13, 2024. Accessed October 16, 2025.
https://tinyurl.com/ms2695jn 3. Villasboas JC, Wallace D, Smith SD, et al. Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY). J Clin Oncol. 2024;42(16_suppl):7058-7058. doi:https://doi.org/10.1200/jco.2024.42.16_suppl.7058
4. A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY). ClinicalTrials.gov. Updated December 13, 2024. Accessed October 16, 2025.
https://www.clinicaltrials.gov/study/NCT04669171 5. Enterome’s Immunotherapy EO2463 Shows Early Clinical Response in Newly Diagnosed Follicular Lymphoma Suggesting a Potential Alternative to ‘Watchful Waiting’. News release. Enterome. December 10, 2024. Accessed October 16, 2025.
https://www.enterome.com/news-events/enteromes-immunotherapy-eo2463-shows-early-clinical-response-in-newly-diagnosed-follicular-lymphoma-suggesting-a-potential-alternative-to-watchful-waiting/ Continue Reading
-
Eye scan shows nerve damage, inflammation in Fabry patients
Noninvasive in vivo confocal microscopy (IVCM) detected signs of nerve damage in the cornea — the eye’s transparent outer layer — in people with Fabry disease, who also had higher levels of inflammatory immune cells in the cornea than…
Continue Reading
-
Strategic entanglements | Pakistan Today
On September 11, Pakistan and Saudi Arabia signed a historic defence pact in the presence of Prime Minister Muhammad Shehbaz Sharif amd COAS Field Marshal Asim Munir. What was a narrative initially concocted during the Pahalgam incident,…
Continue Reading
-
Qnity and SK hynix Sign Long-Term CMP Pad Supply Agreement
About Qnity
Qnity, DuPont’s Electronics business, is a premier technology solutions provider across the semiconductor value chain, empowering AI, high performance computing, and advanced connectivity. From groundbreaking solutions for semiconductor chip manufacturing, to enabling high-speed transmission within complex electronic systems, our high-performance materials and integration expertise make tomorrow’s technologies possible. More information about the company, its businesses and solutions can be found at www.qnityelectronics.com. Investors can access the initial Form 10 filing and amendments for Qnity on its investor website.Qnity™, the Qnity Node Logo, and all products, unless otherwise noted, denoted with ™ or ® are trademarks, trade names or registered trademarks of affiliates of Qnity Electronics, Inc.
About DuPont
DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets, including electronics, transportation, construction, water, healthcare, and worker safety. More information about the company, its businesses, and solutions can be found at www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.
* On January 15, 2025, DuPont de Nemours, Inc. (“DuPont”) announced it is targeting November 1, 2025 to complete the intended separation of its Electronics business (the “Intended Electronics Separation”) by way of a spin-off transaction, thereby creating Qnity Electronics, Inc., a new independent, publicly traded electronics company. The Intended Electronics Separation will not require a shareholder vote and is subject to satisfaction of customary conditions, including final approval by DuPont’s Board of Directors, receipt of tax opinion from counsel, the completion and effectiveness of a Form 10 registration statement with the U.S. Securities and Exchange Commission, applicable regulatory approvals and satisfactory completion of financing.
Cautionary Statement Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements use words such as “plans”, “expects”, “will”, “would”, “anticipates”, “believes”, “intends”, “seeks”, “projects”, “efforts”, “estimates”, “potential”, “continue”, “intend”, “may”, “could”, “should” and similar expressions, among others, as well as other words or expressions referencing future events, conditions or circumstances. Statements that describe or relate to DuPont’s or Qnity’s plans, goals, intentions, strategies, DuPont’s or Qnity’s expectations regarding the Spin-Off, and statements that do not relate to historical or current fact, are examples of forward-looking statements. Forward-looking statements are based on our current beliefs, expectations and assumptions, which may not prove to be accurate, and involve a number of known and unknown risks and uncertainties, many of which are out of DuPont’s and Qnity’s control. Forward-looking statements are not guarantees of future performance, and there are a number of important factors that could cause actual outcomes and results to differ materially from the results contemplated by such forward-looking statements. Additional information concerning these and other factors can be found in DuPont’s and Qnity’s filings with the U.S. Securities and Exchange Commission, including DuPont’s most recent annual report on Form 10-K, most recent quarterly report on Form 10-Q and current reports on Form 8-K and Qnity’s registration statement on Form 10. Any forward-looking statement speaks only as of the date on which it is made. Neither DuPont nor Qnity undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Continue Reading
